ZA200400970B - Novel anticonvulsant derivative salts. - Google Patents
Novel anticonvulsant derivative salts. Download PDFInfo
- Publication number
- ZA200400970B ZA200400970B ZA200400970A ZA200400970A ZA200400970B ZA 200400970 B ZA200400970 B ZA 200400970B ZA 200400970 A ZA200400970 A ZA 200400970A ZA 200400970 A ZA200400970 A ZA 200400970A ZA 200400970 B ZA200400970 B ZA 200400970B
- Authority
- ZA
- South Africa
- Prior art keywords
- salt
- formula
- compound
- alkali metal
- topiramate
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 67
- 239000001961 anticonvulsive agent Substances 0.000 title description 6
- 230000001773 anti-convulsant effect Effects 0.000 title description 4
- 229960003965 antiepileptics Drugs 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 83
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 24
- 229960004394 topiramate Drugs 0.000 claims description 24
- 229910052783 alkali metal Inorganic materials 0.000 claims description 20
- -1 alkali metal salt Chemical class 0.000 claims description 15
- 150000004703 alkoxides Chemical class 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 150000001340 alkali metals Chemical class 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 159000000003 magnesium salts Chemical class 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 159000000000 sodium salts Chemical class 0.000 claims description 9
- 229910052744 lithium Inorganic materials 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims description 6
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims description 6
- 229910000102 alkali metal hydride Inorganic materials 0.000 claims description 5
- 150000008046 alkali metal hydrides Chemical class 0.000 claims description 5
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 229910003002 lithium salt Inorganic materials 0.000 claims description 4
- 159000000002 lithium salts Chemical class 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- 229940096405 magnesium cation Drugs 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical group [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 claims 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical group [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical group C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 claims 1
- 235000017276 Salvia Nutrition 0.000 claims 1
- 241001072909 Salvia Species 0.000 claims 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 claims 1
- 229910000103 lithium hydride Inorganic materials 0.000 claims 1
- 229910000105 potassium hydride Inorganic materials 0.000 claims 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical group [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 208000033001 Complex partial seizures Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 206010040703 Simple partial seizures Diseases 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101500025412 Mus musculus Processed cyclic AMP-responsive element-binding protein 3-like protein 1 Proteins 0.000 description 1
- 208000032005 Spinocerebellar ataxia with axonal neuropathy type 2 Diseases 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 208000033361 autosomal recessive with axonal neuropathy 2 spinocerebellar ataxia Diseases 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940006487 lithium cation Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30396201P | 2001-07-09 | 2001-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200400970B true ZA200400970B (en) | 2005-02-07 |
Family
ID=23174444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200400970A ZA200400970B (en) | 2001-07-09 | 2004-02-05 | Novel anticonvulsant derivative salts. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7098188B2 (xx) |
| EP (1) | EP1414824B1 (xx) |
| JP (1) | JP2005502629A (xx) |
| KR (1) | KR20040013127A (xx) |
| CN (1) | CN1288159C (xx) |
| AR (1) | AR036137A1 (xx) |
| AT (1) | ATE361304T1 (xx) |
| AU (1) | AU2002346042B2 (xx) |
| BR (1) | BR0211063A (xx) |
| CA (1) | CA2452612A1 (xx) |
| DE (1) | DE60219922T2 (xx) |
| DK (1) | DK1414824T3 (xx) |
| ES (1) | ES2284884T3 (xx) |
| HK (1) | HK1064094A1 (xx) |
| HR (1) | HRP20040017A2 (xx) |
| HU (1) | HUP0401080A2 (xx) |
| IL (2) | IL159698A0 (xx) |
| MX (1) | MXPA04000232A (xx) |
| NO (1) | NO20040066L (xx) |
| NZ (1) | NZ530507A (xx) |
| PL (1) | PL367635A1 (xx) |
| PT (1) | PT1414824E (xx) |
| RU (1) | RU2320665C2 (xx) |
| SI (1) | SI21370A (xx) |
| UA (1) | UA78211C2 (xx) |
| WO (1) | WO2003006467A1 (xx) |
| ZA (1) | ZA200400970B (xx) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA78211C2 (en) * | 2001-07-09 | 2007-03-15 | Ortho Mcneil Pharm Inc | Salts of fructopyranose derivatives as anticonvulsant |
| US7041650B2 (en) | 2001-07-09 | 2006-05-09 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivative salts |
| CA2465952A1 (en) * | 2001-11-06 | 2003-05-15 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
| US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
| US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
| EP1494998A2 (en) | 2002-03-01 | 2005-01-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| CA2489984A1 (en) * | 2002-06-21 | 2003-12-31 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| US8183290B2 (en) * | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| US7638291B2 (en) * | 2004-10-25 | 2009-12-29 | Seradyn, Inc. | Immunoassays for topiramate |
| US20060088886A1 (en) * | 2004-10-25 | 2006-04-27 | Anlong Ouyang | Topiramate analogs |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9489372B2 (en) * | 2013-03-15 | 2016-11-08 | Apple Inc. | Web-based spell checker |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| TWI826531B (zh) | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| US20210169844A1 (en) | 2019-12-10 | 2021-06-10 | Tulex Pharmaceuticals Inc. | Compositions and methods for treating epilepsy, seizures and other conditions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4513008A (en) * | 1982-07-30 | 1985-04-23 | The Vinoxen Company, Inc. | Virucidal compositions and therapy |
| US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| AU651244B2 (en) * | 1991-09-19 | 1994-07-14 | Mcneilab, Inc. | Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol |
| US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| US5498629A (en) * | 1993-12-23 | 1996-03-12 | Ortho Pharmaceutical Corporation | Anticonvulsant pseudofructopyranose sulfamates |
| US5998380A (en) * | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
| US5952187A (en) * | 1995-12-01 | 1999-09-14 | Oxis International, Inc. | Topiramate immunoassay |
| US6541520B1 (en) | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| DE60019904T2 (de) * | 1999-02-24 | 2006-05-04 | University Of Cincinnati, Cincinnati | Verwendung von sulfamatderivaten zur behandlung von impulskontrollerkrankungen |
| UA78211C2 (en) | 2001-07-09 | 2007-03-15 | Ortho Mcneil Pharm Inc | Salts of fructopyranose derivatives as anticonvulsant |
| US7041650B2 (en) * | 2001-07-09 | 2006-05-09 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivative salts |
| US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
-
2002
- 2002-03-07 UA UA2004010229A patent/UA78211C2/uk unknown
- 2002-07-03 PL PL02367635A patent/PL367635A1/xx not_active Application Discontinuation
- 2002-07-03 HU HU0401080A patent/HUP0401080A2/hu unknown
- 2002-07-03 AU AU2002346042A patent/AU2002346042B2/en not_active Ceased
- 2002-07-03 CN CNB028172035A patent/CN1288159C/zh not_active Expired - Lifetime
- 2002-07-03 CA CA002452612A patent/CA2452612A1/en not_active Abandoned
- 2002-07-03 JP JP2003512237A patent/JP2005502629A/ja active Pending
- 2002-07-03 SI SI200220021A patent/SI21370A/sl not_active IP Right Cessation
- 2002-07-03 DE DE60219922T patent/DE60219922T2/de not_active Expired - Lifetime
- 2002-07-03 RU RU2004100274/04A patent/RU2320665C2/ru active
- 2002-07-03 DK DK02744798T patent/DK1414824T3/da active
- 2002-07-03 US US10/188,924 patent/US7098188B2/en not_active Expired - Lifetime
- 2002-07-03 PT PT02744798T patent/PT1414824E/pt unknown
- 2002-07-03 IL IL15969802A patent/IL159698A0/xx unknown
- 2002-07-03 AT AT02744798T patent/ATE361304T1/de not_active IP Right Cessation
- 2002-07-03 BR BR0211063-6A patent/BR0211063A/pt not_active IP Right Cessation
- 2002-07-03 MX MXPA04000232A patent/MXPA04000232A/es active IP Right Grant
- 2002-07-03 ES ES02744798T patent/ES2284884T3/es not_active Expired - Lifetime
- 2002-07-03 KR KR10-2004-7000233A patent/KR20040013127A/ko active IP Right Grant
- 2002-07-03 WO PCT/US2002/021016 patent/WO2003006467A1/en active IP Right Grant
- 2002-07-03 NZ NZ530507A patent/NZ530507A/en unknown
- 2002-07-03 EP EP02744798A patent/EP1414824B1/en not_active Expired - Lifetime
- 2002-07-08 AR ARP020102553A patent/AR036137A1/es unknown
-
2004
- 2004-01-02 IL IL159698A patent/IL159698A/en active IP Right Grant
- 2004-01-08 NO NO20040066A patent/NO20040066L/no not_active Application Discontinuation
- 2004-01-09 HR HR20040017A patent/HRP20040017A2/hr not_active Application Discontinuation
- 2004-02-05 ZA ZA200400970A patent/ZA200400970B/en unknown
- 2004-09-08 HK HK04106824A patent/HK1064094A1/xx not_active IP Right Cessation
-
2006
- 2006-01-09 US US11/327,984 patent/US20060105966A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200400970B (en) | Novel anticonvulsant derivative salts. | |
| NZ224219A (en) | Pyrazolo (3,4-d) pyrimidines and pharmaceutical compositions | |
| PL129638B1 (en) | Process for preparing novel derivatives of 6-beta-hydroxymethylpenicillanic acid | |
| ZA200506167B (en) | Novel anticonvulsant derivative salts | |
| EP0196618A1 (en) | 4'-Demethyl-4-epipodophyllotoxin Derivatives, a process for their preparation and their use as medicaments | |
| AU2002346042A1 (en) | Novel anticonvulsant derivative salts | |
| PE20060018A1 (es) | Proceso para la preparacion de haluros de aril y hetoaril-alquilsulfonilo | |
| CN1404476A (zh) | 葡糖苷酶抑制剂及其合成方法 | |
| CA2671816A1 (en) | Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same | |
| ZA200510347B (en) | Asphalt-epoxy resin compositions | |
| US7414126B2 (en) | Process for the preparation of topiramate | |
| AU2009321347A1 (en) | Process for preparing zanamivir and intermediates for use in the process | |
| US9018403B2 (en) | Method for producing tetrahydropyran compound and intermediate thereof | |
| AU2004234110A1 (en) | Heterocyclic compounds for use in the treatment of viral infections | |
| WO2006018807A1 (en) | Crystalline forms of cefdinir | |
| AU2767292A (en) | Cyclic peroxyacetal compounds | |
| KR0178957B1 (ko) | 페넴 화합물 | |
| HU199113B (en) | Process for production of new derivatives of 2,3-diamin-acryl-acid-nitril | |
| DE69707639T2 (de) | Verfahren zur herstellung einer aktivierten aminosäure | |
| PL115848B1 (en) | Process for preparing novel derivatives of vincane | |
| CN114874152B (zh) | 辛弗林苯并噁唑磺酰胺类衍生物、中间体及其制备方法和用途 | |
| EP0366122A2 (en) | Demethylepipodophyllotoxin derivatives | |
| CN114478418A (zh) | 辛弗林砜基四氮唑磺酰胺类衍生物、中间体及其用途 | |
| JP4870296B2 (ja) | ヒノキチオール配糖体の製造方法 | |
| HU207285B (en) | Process for producing n-substituted phenyl-glycine derivatives |